Showing 151-160 of 220 results for "".
- Almirall's Seysara Set to Shake Up US Acne Markethttps://practicaldermatology.com/news/almiralls-seysara-set-to-shake-up-us-acne-market/2457557/The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older is set to shake up the currently stagnant acne market due to its ease of adminis
- Allergan's SkinMedica Tackles Blue Light and More with New LUMIVIVE Systemhttps://practicaldermatology.com/news/skinmedica-tackles-blue-light-and-more-with-new-lumivie-system/2457620/Allergan is launching the SkinMedica LUMIVIVE System, with two distinct formulas - one to shield skin from blue light and environmental aggressors during the day and another to recharge the skin's repair process at night for 24-hour protection and revital
- Ortho Dermatologics Names 2018 Aspire Higher Scholarship Recipientshttps://practicaldermatology.com/news/ortho-dermatologics-names-2018-aspire-higher-scholarship-recipients/2457658/Ortho Dermatologics, a division of Bausch Health Companies Inc., has named the 2018 honorees of the Aspire Higher program, which since 2013 has granted more than $450,000 in scholarships to students who have been affected by dermatologic conditions. This year nine st
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high ri
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meetinghttps://practicaldermatology.com/news/aclaris-to-support-symposium-on-jak-inhibitors-at-the-international-investigative-dermatology-2018-meeting/2457767/Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermato
- Maryland Gets SUNucatedhttps://practicaldermatology.com/news/maryland-gets-sunucated/2457809/And then there were nine. Governor Larry Hogan signed HB 427 into law, making Maryland the second state this year and the ninth one overall to ensure state policy allows students to possess and use sunscreen at school. The legislation is based on the American Society f
- Take That, Kim and Kylie : Most Millennials Don't Want Your Advice on Cosmetic Surgeryhttps://practicaldermatology.com/news/take-that-kim-and-kylie/2457812/When it comes to deciding on nips and tucks, millennials are not inclined to trust social media or celebs, a new
- BTL to Showcase Groundbreaking Research, Latest Innovation at American Society for Laser Medicine & Surgery Annual Conferencehttps://practicaldermatology.com/news/btl-to-showcase-groundbreaking-research-latest-innovation-at-american-society-for-laser-medicine-surgery-annual-conference/2457817/BTL has had nine scientific abstracts and four ePosters accepted for presentation at the 38th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS) tak
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and